Valuation
- Market cap
- 14,466,000
- Revenue TTM
- $0
- Net income TTM
- $-39,220,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 3,233,600
- Avg volume
- 9,478,750
- Day's range
- $0.26 – $0.30
- Shares out
- 49,883,000
- Stochastic %K
- 22%
- Beta
- 0.69
- Analysts
- Strong Sell
- Price target
- $1.77
Company profile
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-tra...
Show more
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 949 354 6499
- Website
- https://www.aeonbiopharma.com
- Address
- 5 Park Plaza, Suite 1750, Irvine, United States
Latest news
No headlines yet.
